<DOC>
	<DOC>NCT02759224</DOC>
	<brief_summary>An Open-Label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics of BRI-1501 Tablet and Coadministration of Lafutidine and Irsogladine maleate as Individual Tablets in Healthy Adult Volunteers</brief_summary>
	<brief_title>A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet</brief_title>
	<detailed_description />
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Lafutidine</mesh_term>
	<mesh_term>Irsogladine</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Healthy subject, aged 19 50 years History of clinically significant and active disease History of gastrointestinal disease History of clinically significant hypersensitivity to study drug, any other drug Laboratory test serum AST or ALT &gt; 1.25 times of upper normal range serum total bilirubin &gt; 1.5 times of upper normal range eGFR &lt; 60 ml/min/1.73mÂ² serological test(HBsAg, HCV Ab, HIV Ag/Ab, Syphilis reagin) positive Hypotension or hypertension Pregnant or nursing women Participation in any other study within 90 days</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>